• 1
    Powers, A. C. 2012. Chapter 344. Diabetes mellitus. In A. S. Fauci, D. L. Kasper, J. L. Jameson, D. L. Longo and S. L. Hauser, eds. Harrison's principles of internal medicine. 18th ed. McGraw-Hill, New York, NY. Available at (accessed 8 August 8 2013).
  • 2
    Triplitt, C. L., and C. A. Reasner. 2011. Chapter 83. Diabetes mellitus. In J. T. DiPiro, R. L. Talbert, G. C. Yee, G. R. Matzke, B. G. Wells and L. M. Posey, eds. Pharmacotherapy: a pathophysiologic approach. 8th ed. McGraw-Hill, New York, NY. Available at (accessed August 8, 2013).
  • 3
    Kunjathaya, P., K. Ramswami, A. N. Krishnamurthy, and N. Bhat. 2013. Acute necrotizing pancreatitis associated with vildagliptin. JOP 14:8184.
  • 4
    Iyer, S. N., A. J. Drake III, R. L. West, C. E. Mendez, and R. J. Tanenberg. 2012. Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide. Endocr. Pract. 18:e10e13.
  • 5
    Garg, R., C. Hussey, and S. Ibrahim. 2010. Pancreatitis associated with the use of sitagliptin and orlistat combination: a case report. Diabet. Med. 27:485486.
  • 6
    Saraogi, R., R. Mallik, and S. Ghosh. 2012. Mild acute pancreatitis with vildagliptin use. Indian J. Endocrinol. Metab. 16(Suppl. 2):S480S482.
  • 7
    Girgis, C. M., and B. L. Champion. 2011. Vildagliptin-induced acute pancreatitis. Endocr. Pract. 17:e48e50.
  • 8
    Sue, M., A. Yoshihara, K. Kuboki, N. Hiroi, and G. Yoshino. 2013. A case of severe acute necrotizing pancreatitis after administration of sitagliptin. Clin. Med. Insights Case Rep. 6:2327.
  • 9
    U.S. Department of Health & Human Services, U.S. Food & Drug Administration. 2009. Information for healthcare professionals—acute pancreatitis and sitagliptin (marketed as Januvia and Janumet). Available at (accessed 8 August 2013).
  • 10
    Raschi, E., C. Piccinni, E. Poluzzi, F. Marchesini, and F. De Ponti. 2011. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetol. 50:569577.
  • 11
    Institute for Safe Medication Practices. 2013. Perspectives on GLP-1 agents for diabetes. Available at (accessed April 18, 2013).
  • 12
    Singh, S., H. Chang, T. Richards, J. Weiner, J. Clark, J. Segal. 2013. Glucagonlike peptide 1–based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus. JAMA Intern. Med. 173:534539.
  • 13
    Dore, D. D., J. D. Seeger, and K. Arnold Chan. 2009. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr. Med. Res. Opin. 25:10191027.
  • 14
    Garg, R., W. Chen, and M. Pendergrass. 2010. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 33:23492354.
  • 15
    Butler, A. E., M. Campbell-Thompson, T. Gurlo, D. W. Dawson, M. Atkinson, and P. C. Butler. 2013. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 62:25952604.
  • 16
    Egan, A. G., E. Blind, K. Dunder, P. A. de Graeff, B. T. Hummer, T. Bourcier, et al. 2014. Pancreatic safety of incretin-based drugs- FDA and EMA assessment. N. Engl. J. Med. 370:794797.
  • 17
    Lando, H. M., M. Alattar, and A. P. Dua. 2012. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptyidyl-peptidase-4 inhibitors in the outpatient setting. Endocr. Pract. 18:472477.
  • 18
    Matveyenko, A. V., S. Dry, H. I. Cox, A. Moshtaghian, T. Gurio, R. Galasso, et al. 2009. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 58:16041615.
  • 19
    Busch, S. J., P. Hoffmann, P. Sohata, R. Johnson, W. Kothny, F. Meyer, et al. 2013. Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man. Diabetes Obes. Metab. 15:7276.
  • 20
    Mentlein, R. 1999. Dipeptidyl-peptidase IV, (CD26)-role in the inactivation of regulatory peptides. Regul. Pept. 85:924.
  • 21
    Drucker, D. J., S. I. Sherman, R. M. Bergenstal, and J. B. Buse. 2011. The safety of incretin-based therapies—review of the scientific evidence. J. Clin. Endocrinol. Metab. 96:20272031.
  • 22
    Kanbay, M., H. Selcuk, U. Yilmaz, and S. Boyacioglu. 2006. Recurrent acute pancreatitis probably secondary to lisinopril. South. Med. J. 99:13881389.
  • 23
    Muchnick, J. S., and J. L. Mehta. 1999. Angiotensin converting enzyme inhibitor induced pancreatitis. Clin. Cardiol. 22:5051.
  • 24
    Kanbay, M., M. Korkmaz, U. Yilmaz, G. Gur, and S. Boyacioglu. 2004. Acute pancreatitis due to ramipril therapy. Postgrad. Med. J. 80:617618.
  • 25
    lliopoulou, A., G. Giannakopoulos, H. Pagoy, T. Christos, and S. Theodore. 2001. Acute pancreatitis due to captopril treatment. Dig. Dis. Sci. 46:18821883.